Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WA | N.MMED.WR | N.MMED.WS | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Comment by josameyeron Feb 28, 2012 12:18pm

392 Views

Post# 19598369

RE: Financing

They also collected a few million from Can Gold and Everton ,re the sale of the Dominican and Mexican property, also I believe they might have collected some from CallaisResources,re the outstanding note to Brigus. Plus, they have to be earning some money from current gold sales. I stand corrected if i am wrong.I agree that with the current price of gold, it would make sense to buy back a portion from Sandstorm if at all possible.,Cheers Josa.

Bullboard Posts

98% energy efficiency: How Acceleware's EM Technology is transforming heat solutions